Assessment of cellular response to mitogens in long-term allogeneic hematopoietic stem cell transplantation survivors.


Journal

International journal of hematology
ISSN: 1865-3774
Titre abrégé: Int J Hematol
Pays: Japan
ID NLM: 9111627

Informations de publication

Date de publication:
Dec 2021
Historique:
received: 22 04 2021
accepted: 18 08 2021
revised: 17 08 2021
pubmed: 23 8 2021
medline: 17 12 2021
entrez: 22 8 2021
Statut: ppublish

Résumé

Infection is one of the major causes of death in hematopoietic stem cell transplantation (HSCT) survivors. Precise assessments of immune function after HSCT will be critical in establishing appropriate treatment and prophylaxis, such as re-vaccination. Although several surrogate markers for prediction of clinical outcomes after HSCT have been proposed, definitive markers of immune reconstitution and data on those markers in long-term survivors are lacking. In this study, cellular response to mitogens was assessed and clinical features associated with a poor response to mitogens were investigated in long-term allogeneic HSCT survivors. Age at transplantation and age at the time of mitogen stimulation test were each identified as significant risk factors for poor response to phytohemagglutinin and concanavalin A, respectively (P < 0.001 each). However, time elapsed since transplantation was not found to be correlated with responsiveness to mitogens in this study. Prospective, in-depth studies on immune reconstitution are needed to establish appropriate prophylaxis against infections after HSCT and a schedule for re-vaccination.

Identifiants

pubmed: 34420193
doi: 10.1007/s12185-021-03206-7
pii: 10.1007/s12185-021-03206-7
doi:

Substances chimiques

Mitogens 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

682-690

Informations de copyright

© 2021. Japanese Society of Hematology.

Références

Kanate AS, Majhail NS, Savani BN, Bredeson C, Champlin RE, Crawford S, et al. Indications for hematopoietic cell transplantation and immune effector cell therapy: guidelines from the American society for transplantation and cellular therapy. Biol Blood Marrow Transplant. 2020;26(7):1247–56.
doi: 10.1016/j.bbmt.2020.03.002
Tomblyn M, Chiller T, Einsele H, Gress R, Sepkowitz K, Storek J, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant. 2009;15(10):1143–238.
doi: 10.1016/j.bbmt.2009.06.019
Majhail NS, Tao L, Bredeson C, Davies S, Dehn J, Gajewski JL, et al. Prevalence of hematopoietic cell transplant survivors in the United States. Biol Blood Marrow Transplant. 2013;19(10):1498–501.
doi: 10.1016/j.bbmt.2013.07.020
Majhail NS, Douglas RJ. Surviving the cure: long term followup of hematopoietic cell transplant recipients. Bone Marrow Transplant. 2013;48(9):1145–51.
doi: 10.1038/bmt.2012.258
Cordonnier C, Einarsdottir S, Cesaro S, Di Blasi R, Mikulska M, Rieger C, et al. Vaccination of haemopoietic stem cell transplant recipients: guidelines of the 2017 European Conference on Infections in Leukaemia (ECIL 7). Lancet Infect Dis. 2019;19(6):e200–12.
doi: 10.1016/S1473-3099(18)30600-5
Ljungman P, Cordonnier C, Einsele H, Englund J, Machado CM, Storek J, et al. Vaccination of hematopoietic cell transplant recipients. Bone Marrow Transplant. 2009;44(8):521–6.
doi: 10.1038/bmt.2009.263
Geddes M, Storek J. Immune reconstitution following hematopoietic stem-cell transplantation. Best Pract Res Clin Haematol. 2007;20(2):329–48.
doi: 10.1016/j.beha.2006.09.009
Fritze D, Dystant P. Detection of impaired mitogen responses in autologous whole blood of cancer patients using an optimized method of lymphocyte stimulation. Immunol Lett. 1984;8(5):243–7.
doi: 10.1016/0165-2478(84)90003-8
Bloemena E, Roos MT, Van Heijst JL, Vossen JM, Schellekens PT. Whole-blood lymphocyte cultures. J Immunol Methods. 1989;122(2):161–7.
doi: 10.1016/0022-1759(89)90260-3
Guideline Committee of JSHCT. Vaccinations Ver. 2. Guideline of the Japan Society for Hematopoietic Cell Transplantation, vol. 1, Osaka: Iyaku Journal; 2014. p. 162–206.
Guideline Committee of JSHCT. Vaccinations Ver.3. Guideline of the Japan Society for Hematopoietic Cell Transplantation [Internet]. 2018; 1:1–50. Available from: https://www.jshct.com/uploads/files/guideline/01_05_vaccination_ver03.pdf . Accessed 20 Jul 2021.
Kanda Y. Investigation of the freely available easy-to-use software “EZR” for medical statistics. Bone Marrow Transplant. 2013;48(3):452–8.
doi: 10.1038/bmt.2012.244
Morecki S, Gelfand Y, Nagler A, Or R, Naparstek E, Varadi G, et al. Immune reconstitution following allogeneic stem cell transplantation in recipients conditioned by low intensity vs myeloablative regimen. Bone Marrow Transplant. 2001;28(3):243–9.
doi: 10.1038/sj.bmt.1703118
Yong MK, Cameron PU, Slavin MA, Cheng AC, Morrissey CO, Bergin K, et al. Low T-cell responses to mitogen stimulation predicts poor survival in recipients of allogeneic hematopoietic stem cell transplantation. Front Immunol. 2017;8:1506.
doi: 10.3389/fimmu.2017.01506
Shiobara S, Ueda M, Harada M, Mori T, Matsue K, Nakao S, et al. Long-term observation of immunologic reconstitution after allogeneic bone marrow transplantation: differences in recovery among functional T cell subsets. Nihon Ketsueki Gakkai Zasshi. 1989;52(1):55–62.
pubmed: 2662696
Soiffer RJ, Bosserman L, Murray C, Cochran K, Daley J, Ritz J. Reconstitution of T-cell function after CD6-depleted allogeneic bone marrow transplantation. Blood. 1990;75(10):2076–84.
doi: 10.1182/blood.V75.10.2076.2076
Israeli M, Klein T, Herscovici C, Ram R, Shpilberg O, Sredni B, et al. Cellular immune function monitoring after allogeneic haematopoietic cell transplantation: evaluation of a new assay. Clin Exp Immunol. 2013;172(3):475–82.
doi: 10.1111/cei.12072
Jo Y, Lim J, Kim Y, Han K, Min W-S, Oh E-J. CD4 T-cell function assay using Cylex ImmuKnow and lymphocyte subset recovery following allogeneic hematopoietic stem cell transplantation. Transpl Immunol. 2015;33(2):78–83.
doi: 10.1016/j.trim.2015.09.001
Gesundheit B, Budowski E, Israeli M, Shapira MY, Resnick IB, Bringer R, et al. Assessment of CD4 T-lymphocyte reactivity by the Cylex ImmuKnow assay in patients following allogeneic hematopoietic SCT. Bone Marrow Transplant. 2010;45(3):527–33.
doi: 10.1038/bmt.2009.182
Hicks MJ, Jones JF, Thies AC, Weigle KA, Minnich LL. Age-related changes in mitogen-induced lymphocyte function from birth to old age. Am J Clin Pathol. 1983;80(2):159–63.
doi: 10.1093/ajcp/80.2.159
Wherry EJ, Kurachi M. Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol. 2015;15(8):486–99.
doi: 10.1038/nri3862

Auteurs

Takahiko Sato (T)

Department of Hematology, Japanese Red Cross Nagoya First Hospital, 3-35, Michishita-cho, Nakamura-ku, Nagoya, Aichi, Japan. t.sato@med.nagoya-u.ac.jp.
Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan. t.sato@med.nagoya-u.ac.jp.

Miyo Goto (M)

Department of Hematology, Japanese Red Cross Nagoya First Hospital, 3-35, Michishita-cho, Nakamura-ku, Nagoya, Aichi, Japan.

Marie Ohbiki (M)

Department of Hematology, Japanese Red Cross Nagoya First Hospital, 3-35, Michishita-cho, Nakamura-ku, Nagoya, Aichi, Japan.

Tatsunori Goto (T)

Department of Hematology, Japanese Red Cross Nagoya First Hospital, 3-35, Michishita-cho, Nakamura-ku, Nagoya, Aichi, Japan.

Takanobu Morishita (T)

Department of Hematology, Japanese Red Cross Nagoya First Hospital, 3-35, Michishita-cho, Nakamura-ku, Nagoya, Aichi, Japan.

Aika Seto (A)

Department of Hematology, Japanese Red Cross Nagoya First Hospital, 3-35, Michishita-cho, Nakamura-ku, Nagoya, Aichi, Japan.

Yukiyasu Ozawa (Y)

Department of Hematology, Japanese Red Cross Nagoya First Hospital, 3-35, Michishita-cho, Nakamura-ku, Nagoya, Aichi, Japan.

Koichi Miyamura (K)

Department of Hematology, Japanese Red Cross Nagoya First Hospital, 3-35, Michishita-cho, Nakamura-ku, Nagoya, Aichi, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH